Background The timing of the initial spread of hepatitis C virus genotype 1a in North America is controversial. In particular, how and when hepatitis C virus reached extraordinary prevalence in specifi c demographic groups remains unclear. We quantifi ed, using all available hepatitis C virus sequence data and phylodynamic methods, the timing of the spread of hepatitis C virus genotype 1a in North America.
Introduction
Hepatitis C virus is a global threat to public health with an estimated 185 million people infected worldwide, including 4·6 million infections of predominantly genotype 1a in North America. 1 The North American epidemic is composed of 3·5 million infections in the USA, 300 000 infections in Canada, and 900 000 in Mexico. 1 Infected individuals are at high risk of liver cirrhosis, hepatocellular carcinoma, and liver failure, leading to early mortality and high cost to the health-care system. About 75% of adults infected with hepatitis C virus in North America were born between 1945 and 1964 (so-called baby boomers). 2 The mechanism by which hepatitis C virus reached such high prevalence in this cohort is unclear. Previous studies have implicated the use of infected blood products before the advent of rigorous screening of the blood supply for infectious agents in the early 1990s, or injection drug use, which peaked in North America at the end of the 1960s. 3, 4 However, despite mixed evidence in the published work, the dominant view is that the baby boomer epidemic in North America is largely attributable to past sporadic risky behaviours (ie, experimentation with injection drug use, unsafe tattooing, high risk sex, travel to high prevalence areas) 2, 5, 6 and transfusion with infected blood.
Many RNA viruses, including hepatitis C virus, evolve rapidly and therefore it is possible to approximate the recent transmission history of an epidemic from the genetic divergence of infections sampled from the population. 7 This genetic diversity is structured by the shared ancestries of the infections, which can be reconstructed from these sequences as a tree-based model known as a phylogeny. Since most of the hepatitis C virus genome evolves at roughly 0·001 substitutions per site per year, 8, 9 it is possible to use the collection dates of diff erent samples to rescale the phylogeny such that the branching points in the tree approximate the dates of transmission events in the epidemic. 10 Thus, the shape of the phylogeny contains valuable information about the epidemiological dynamics of the virus population, 11, 12 which can be extracted by fi tting epidemic or population genetic models to these data. Such techniques have provided key insights into epidemics including HIV, infl uenza A virus, dengue virus, and Ebola virus infection. 4, 7, 13 Many of these studies focused on the eff ective number of infections, which is a quantity expected to be proportional to prevalence during the exponential phase of an epidemic, but which should not in general be mistaken as equivalent to prevalence.
In this retrospective longitudinal study, we used a distribution of phylogenetic trees of all published sequences covering fi ve hepatitis C virus genes to infer the past trajectories in the eff ective number of infections in the North American genotype 1a epidemic. We focused on the genotype 1a epidemic because it is overwhelmingly the dominant hepatitis C virus genotype circulating in North America. 1 We assessed the progression of the epidemic over time to test whether the timing of the spread of hepatitis C virus in North America matches the previously hypothesised periods of high incidence. If the dynamics of the hepatitis C virus epidemic in North America have primarily been driven by injection drug use or the use of infected blood products, then we would expect the eff ective number of infections to be highest later in the progression of the epidemic-namely, at the end of the 1960s and early 1970s.
Methods

Data collection
We retrieved all available records of hepatitis C virus sequences from the National Center for Biotechnology Information Genbank nucleotide database (appendix p 12). The search results, consisting of 160 556 records, were reduced to 45 316 sequences by excluding any sequence lacking a source modifi er fi eld (attribute information associated with the sequence) or a collection date.
Specifi c gene regions were extracted from these data by pairwise alignment of each sequence against the respective sequence intervals from the H77 reference genome and extracting the overlapping region. Each gene-specifi c dataset was manually inspected and clipped to extract the broadest interval with the greatest overlap across sequences. We selected genomic regions for analyses on the basis of previous whole genome studies of hepatitis C virus genotype 1, which showed that E2, NS2, and NS5B were the most informative gene regions for phylodynamic studies. 4 We also analysed the E1 and NS4B regions. 
Data curation
To screen for genotype 1a sequences, genotype and gene-specifi c reference sequences were collected from the Los Alamos National Laboratory hepatitis C virus sequence repository. We aligned sequences in each dataset using MAFFT (version 7.154b) and manually inspected them using HYPHY (version 2.22 
Implications of all the available evidence
The spread of hepatitis C virus genotype 1a in North America and dominance in baby boomers was a result of early expansion because of both iatrogenic and risky behaviours, followed by transmission due to intravenous drug use in later years as medical technology and blood supply screening prevented iatrogenic transmission.
Eff ective number of infections
We reconstructed the dynamics of the epidemic using Bayesian skyline plots, a non-parametric smoothing method for approximating past population dynamics. 15 The y axis in a Bayesian skyline plot represents N e multiplied by τ, where N e is the eff ective population size and τ is the generation time. The y axis can be interpreted as the number of infected individuals who go on to infect additional individuals (eff ective number of infections 16 ), and the x axis represents time. A minimum of four replicate Markov chain Monte Carlo samples were run in BEAST (version 1.8.0) for each gene, for at least 5 × 10⁸ generations per run. To determine if choice of priors on both the model by which sequences accrue changes (substitution models) or the model by which the expected number of changes in a sequence relates to time (clock models) biased the results, we did two runs for each gene with four diff erent substitution models (General Time Reversible and Tamura-Nei 93 with and without γ distributed rate variation) and three diff erent clock models (strict, random local, and relaxed). To determine the best fi tting model, we compared models in the programme Tracer (version 1.5) using Bayes factors. 10 The optimum run conditions were a General Time Reversible substitution model with among-site rate heterogeneity distributed according to a γ distribution under a relaxed molecular clock. The convergence of each run was assessed through evaluation of parameter traces and eff ective sample size greater than 200 via Tracer (version 1.5).
Role of the funding source
The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The fi gure shows Bayesian skyline plots reconstructing the spread of the genotype 1a epidemic of hepatitis C virus in North America for all analysed genomic regions; the appendix (p 16) shows each individual gene region. Taken together, the analyses of all gene regions suggest that the greatest expansion of the epidemic in North America occurred between 1940 and 1965. The exponential growth phase of the epidemic had subsided by 1965, suggesting a plateau in the rate of spread between 1965 and 1989, then dropped during the early 1990s. There has been a slight increase in the eff ective number of hepatitis C virus infections since the early 2000s (fi gure). Analyses of each gene separately show substantial variation in estimates of the timing of the early exponential growth, ranging roughly from 1940 for NS2, to 1965 for NS4B (fi gure). We had the greatest confi dence in the peak spread across all genes between 1948 and 1963. In sum, our phylogenetic analyses strongly suggest that the hepatitis C virus genotype 1a epidemic in North America had already attained the height of its distribution by 1960.
Discussion
Our results suggest that the hepatitis C virus genotype 1a epidemic underwent rapid expansion between 1940 and 1960. There followed a period of relatively little growth in the epidemic, a subsequent decline during the early 1990s, and a small increase in the late 1990s and early 2000s. These analyses suggest the period of greatest increase in North America was substantially earlier than previously suggested. 4 Potential causes of a substantial early expansion (1940-60) of the epidemic are diverse, coinciding with the increase in medical procedures during and immediately following World War 2, 4,19,20 when injection and blood transfusion technologies were still in their infancy, 20, 21 and with the expansion of recreational injection drug use in North America and associated needle sharing between 1920 and the late 1960s. 3, 5 Many medical procedures have been linked to the spread of hepatitis C virus including use of contaminated multidose vials, [22] [23] [24] fi nger stick devices, 25 and surgical procedures. 26 The spread of hepatitis C virus in North America through iatrogenic sources between 1940 and 1960 is consistent with evidence of iatrogenic spread in other high-income regions over the same period-eg, in Russia, 27 France, 28 and Japan. 20, 27 Injection drug use became more common in North America in the late 1960s, suggesting that if this was the main driver of the epidemic, the period of peak expansion of the hepatitis C virus epidemic would have coincided with the peak of injection drug use rather than much earlier as shown by our analyses.
The plateau in the spread of hepatitis C virus between 1960 and 1990 is consistent with the hypothesis that changes in injection technology were a driving factor. Before 1950, injection technology was characterised by machine-made glass and metal syringes, which were typically sterilised manually and reused because of their high cost. 21 Between 1950 and 1960, such syringes were phased out and replaced by disposable plastic single-use syringes. 21 Since 1960, reuse of medical syringes has been greatly reduced in North America. 21 The spread of hepatitis C virus during this plateau period could have been maintained by a combination of injection drug use 3, 4 and transfusion of infected blood products before the introduction of rigorous screening of blood supplies in 1992. 17 Before 1992, the incorporation of plasma infected with hepatitis C virus into the blood supply often resulted in nosocomial transmission during medical procedures involving the transfusion of blood or organ transplantation. 17 However, transmission of hepatitis C virus via infected blood products combined with transmission through injection drug use probably occurred at a rate suffi cient to maintain the eff ective population size of hepatitis C virus. 3, 5, 6 This hypothesis is further supported by the decline in spread in the early 1990s coincident with the advent of rigorous screening of blood products 17 and with the widespread penetration of needle exchange programmes into communities of injection drug users. 18 The slight upturn in eff ective population size just after the year 2000 is consistent with epidemiological evidence of both increases in hepatitis C virus infection among young injection drug users who reside in nonurban areas, 29 and a signifi cant increase in infections among men who have sex with men. 30 Because of the paucity of samples with early collection dates, previous studies of genotype 1a population dynamics used sequences collected mainly between 2000 and 2010. For example, a landmark study 4 Based on our results, the oldest members of the demographic cohort with the highest burden of hepatitis C virus (the baby boomers) were roughly 5 years of age around the peak of the spread of genotype 1a in North America in 1950. Thus, it is unlikely that past sporadic risky behaviour (experimentation with injection drug use, unsafe tattooing, high risk sex, travel to endemic areas) was the dominant route of transmission in this group. However, infection with hepatitis C virus in this cohort certainly occurred through injection drug use thereafter, and remains a dominant source of new infections. 5, 6 Limitations of this analysis include the fact that phylogenetic methods of dating ancestors from genetic sequences are sensitive to invalid model assumptions 13 making it diffi cult to confi dently pinpoint a diff erence of 10-20 years in the past. The inclusion of more older sequences obtained from archived samples would be of great value in refi ning estimates of the timing of the spread while improving confi dence intervals around the estimates. It is not unusual for molecular clock estimates to have broad confi dence intervals when reconstructing events deep in the tree; furthermore, our gene-specifi c datasets did not overlap completely. Thus, we were integrating sequences derived from diff erent genomes that have been subjected to diff erent environments. We should not therefore expect the confi dence limits on these diff erent gene-specifi c datasets to be highly concordant in the remote past.
In summary, our data indicate that the rapid and large-scale expansion of hepatitis C virus transmission in North America was coincident with increases in medical procedures that began after World War 2 (nosocomial or iatrogenic causes), and not only the rise in injection drug use, which peaked much later in North America, in the late 1960s. 3 Thus, the prevailing view that the North American epidemic is predominately attributable to past sporadic risky behaviours is not supported by our data. Belief that risky behaviours were the dominant route of infection in North America could bias providers and patients against screening. Our results could help to reduce stigma related to screening and diagnosis of hepatitis C virus, potentially increasing the numbers of providers off ering screening, patients accepting testing, and if positive, presenting for care and treatment. Because of vast improvements in medical technology, particularly in syringe manufacture and guidelines for their use, nosocomial factors that contributed to the early spread of hepatitis C virus in North America 4 no longer have a major role in the epidemic.
